Acute Lymphoblastic Leukemia (ALL) |

Besponsa: Is this really a viable new treatment for ALL?

Posted on August 18, 2017 by by

thassodotcom Posted in New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

August 18, 2017 – B-cell precursor acute lymphoblastic leukemia (ALL) is a aggressive and rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. In the United States, the National Cancer Institute estimates that approximately 5,970 people will be diagnosed with B-cell ALL this year and approximately 1,440 will die from the disease.

…

Inherited risk factors increase odds of developing childhood acute lymphoblastic leukemia (ALL)

Posted on January 16, 2010 by by

thassodotcom Posted in Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Pharmacogenetics No Comments ↓

January 16, 2010 – This contribution has just been published in the ScienceBlog – Pharmacogenetics at this locoation. It is presented here in its original state and with all credentials and rights resting with the original author.

Scientists at St. Jude Children’s Research Hospital have identified inherited variations in two genes that account for 37 percent of childhood acute lymphoblastic leukemia (ALL),

…